Upfront Cash ($M)

Upfront Equity ($M)

Contingent Equity ($M)

R&D Support ($M)

Dev / Reg Milestones ($M)

Other Milestones ($M)

Total Precommercial Payments ($M)

Sales Milestones ($M)

Upfront Share (%)

Marketing Fee (%)

Transfer Price (%)

Manufacture Cost + (%)

neurotrophic tyrosine kinase receptor 1 (NTRK1), c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1)

tiered royalties | upfront payment, R&D fees, and potential milestone payments totaling $189M

Africa, Asia, Europe, Middle East, NAFTA, South America

All African Countries, All European Countries, All Middle East Countries, All NAFTA Countries, All South American Countries, Australia, India, Japan, New Zealand, Other Asian

Tiered, double-digit royalties | $5M payment made during the first 12 months of the agreement or upon Nicoya achieving a certain predetermined development milestone | Up to $115M in development, regulatory and sales-based milestones

undisclosed upfront payment | $30M in development, regulatory, and commercial milestones

Asthma, Chronic Obstructive Pulmonary Disease, Cystic Fibrosis

Tiered double-digit royalties | $179M in clinical, regulatory, and commercial milestones

glutaminyl-peptide cyclotransferase (QPCT) (glutaminyl cyclase) (QC), beta-amyloid (AB)

double-digit royalties | Undisclosed upfront payment and development and sales milestones totaling $565M

Endocrinological & Metabolic, Other/Miscellaneous

Genetic Disorders, Other Endocrinological & Metabolic

Efmody, Alkindi, Alkindi Sprinkle, Infacort, Chronocort, hydrocortisone extended release, NSC-10483

B-Raf proto-oncogene serine/threonine-protein kinase (p94) (BRAF), fibroblast growth factor (FGF) receptor 1 (FGFR1) (CD331), fibroblast growth factor (FGF) receptor 2 (FGFR2) (keratinocyte growth factor receptor) (KGFR)

IBD - Crohn's Disease, IBD - Ulcerative Colitis, Other Gastrointestinal

Tiered low double-digit royalties | Up to $200M in development and commercial milestones

$92M, per Milestone's 6Q21 | $5M of pre-funded warrants, per Milestone's 6Q21 | low to high double-digit royalty, per Milestone's 6Q21 | $15.5M, per Milestone's 6Q21

$180M, per Mirati's 6Q21 | High-teen to low twenties royalties, per Mirati's 6Q21 | $93M, per Mirati's 6Q21

Iluvien, Medidur FA, fluocinolone acetonide intravitreal implant, DF-277, NSC-92339

Liver & Gallbladder Diseases, Other/Miscellaneous

Genetic Disorders, Other Liver & Gallbladder Diseases

solute carrier family 10 sodium-dependent bile acid transporter member 2 (SLC10A2) (ASBT) (IBAT)

double-digit tiered royalties | $109M in regulatory and commercial milestones

$444M in sales milestones | $31M in Series A Preferred Stock investment | Royalty rates ranging from high single digits to the low twenties | $43M in development fees

Central Nervous System, Liver & Gallbladder Diseases

Cirrhosis/Scarring, Other Central Nervous System

Tiered low double-digit royalties | $105M in development and commercial milestones

Autoimmune/Inflammatory, Central Nervous System

CD79b molecule immunoglobulin-associated beta (CD79B) (B29), Fc gamma receptor IIb (FCGR2B) (CD32B)

Up to $11.5 million in research, development and manufacturing funding | Low-to-mid double digit royalties | Up to $172M in development, regulatory and commercial milestones

low double digit royalty, per Scynexis' 3Q21 | $110M in agg milestones, per Scynexis' 3Q21

mechanistic target of rapamycin (serine/threonine kinase) (mTOR) (FRAP) (FRAP1) (FRAP2) (RAFT1) (RAPT1), T lymphocyte

Tiered royalties | upfront payment, regulatory and sales milestone payments totaling up to $271M

Broad Focus Autoimmune/Inflammatory, Other Autoimmune/Inflammatory

568.2K Zai shares @ $132/sh, per argenx' 2020 Form 20-F | $75M in dev cost reimb, per argenx' 2020 Form 20-F | Mid-teen to low twenties royalties, per argenx' 2020 Form 20-F | $25M on US approval, per argenx' 2020 Form 20-F

Endocrinological & Metabolic, Other/Miscellaneous

Genetic Disorders, Other Endocrinological & Metabolic

Efmody, Alkindi, Alkindi Sprinkle, Infacort, Chronocort, hydrocortisone extended release, NSC-10483

Guohong Guokang Health Technology Development

$215M, per Turning Point's 2020 10-K | mid-teen to low twenties royalties, per Turning Point's 2020 10-K | $121M, per Turning Point's 2020 10-K

Yangtze River Pharmaceutical, Shanghai Haini Pharmaceutical

$40M upfront from JV, per Allogene's 2020 10-K | Overland purchase 51% of JV for $117M, per Allogene's 2020 10-K | low to mid-single digit royalties, per Allogene's 2020 10-K | $40M in reg milestones from JV, per Allogene's 2020 10-K | 49% of JV owned by Allogene, per Allogene's 2020 10-K

high-single-digit to low-teen royalties, per Zai's 2020 10-K | $211M in agg milestones, per Cullinan's IPO prospectus

high single to low double-digit royalties, per Sellas' 2020 10-K | $194.5M in agg milestones, per Sellas' 2020 10-K

low double digit to mid-teen royalty, per Aravive's 2020 10-K | $207M in agg milestones, per Aravive's 2020 10-K

Up to double-digit royalties | $135M in development, regulatory, commercial milestones

high single-digit to mid double-digit royalties, per CASI's 2020 10-K | $83M in agg milestones, per CASI's 2020 10-K

$185M, per ImmunoGen's 2020 10-K | low double-digit to high teen royalties, per ImmunoGen's 2020 10-K | $80M, per ImmunoGen's 2020 10-K

Low-double-digit royalties | $50M in development, regulatory and sales milestones

Tiered royalties ranging from the low teens to low-twenties, per Ocular's 9Q20 | $91M in agg milestones, per Ocular's 9Q20

115,928,803 CStone shares at a price of US$1.725 per share, 9.9% equity stake | $280M in milestones

Avastin biosimilar, Mvasi, bevacizumab biosimilar, M511, mAbxience, BAT1706, IBI 305, LY01008

fibroblast growth factor (FGF) receptor (FGFR), tyrosine-protein phosphatase non-receptor type 11 (PTPN11) (SHP-2) (protein-tyrosine phosphatase 1D) (PTP-1D) (protein-tyrosine phosphatase 2C) (PTP-2C)

BridgeBio will increase its equity interest via investment in LianBio | Tiered royalty payments from single- to double-digits | $505M in milestone payments

MyoKardia will receive an equity stake in Lian Cardiovascular | Tiered double-digit royalties | $147.5M in regulatory and sales milestones

mid single-digit royalty, per Eyenovia's 6Q20 | $41.75, per Eyenovia's 6Q20 | AV pays CON % of 2nd generation dev costs

epidermal growth factor receptor type 2 (HER2) (ERBB2) (receptor tyrosine-protein kinase erbB-2)

$385M, per Assembly's 9Q20 | BeiGene pays up to $45M in dev/reg costs in China, then equally shared, per Assembly's 9Q20 | mid-teen to low thirties royalties, per Assembly's 9Q20 | $113.8M, per Assembly's 9Q20

2M shares @ $25/sh | low- to high-teen royalties, per Cytokinetics' 9Q20 | $90M in contingent funding for 4% royalty to RTW until repaid in full, per Cytokinetics' 9Q20 | $200M in agg milestones, per Cytokinetics' 9Q20

Lee’s Pharmaceutical, Zhaoke Ophthalmology Pharmaceutical

Undisclosed upfront payment | Development, regulatory and commercial milestones of up to $68 million

c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1), anaplastic lymphoma receptor tyrosine kinase (ALK) (CD246) (anaplastic lymphoma kinase) (ALK tyrosine kinase receptor)

$105M, per Turning Point's 6Q20 | mid- to high-teen royalties, per Turning Point's 6Q20 | $46M, per Turning Point's 6Q20

balstilimab, AGEN-2034, RebmAb-700, zalifrelimab, AGEN-1884, RebmAb-600

programmed cell death 1 (PD-1) (PDCD1) (CD279), cytotoxic T-lymphocyte-associated protein 4 (CTLA4) (CD152)

4.96M shares @ $4.03/sh | Mid single-digit to low twenties royalties, per Agenus' 6Q20 | $100M in agg milestones, per Agenus' 6Q20

PrimaryPeptides_QingdaoPrimedicine_051920.pdf

VenusMedtech_OpusMedicalTherapies_050220.pdf

tropomyosin receptor kinase A (TrkA), tropomyosin receptor kinase B (TrkB), tropomyosin receptor kinase C (TrkC)

Alphamab, Jiangsu Alphamab Biopharmaceuticals

Comirnaty, Pfizer-BioNTech Covid-19 Vaccine, tozinameran, BNT162, PF-07302048, BNT162B2

USD 50 million (EUR 44 million) for 1,580,777 ordinary shares in BioNTech | $1M, per BioNTech's 7/20 prospectus | $70M, per BioNTech's 7/20 prospectus | 30-39% royalty, per BioNTech's 7/20 prospectus | $14M, per BioNTech's 7/20 prospectus

Xipere, triamcinolone acetonide suprachoroidal injectable suspension, CLS-TA

10-12% royalty, per Clearside's 3Q20 | $31.5M in agg milestones, per Clearside's 3Q20

glucocorticoid receptor (GCCR), G protein-coupled receptor 133 (GPR133)

Sinotek-Advocates International, Beijing Zhonghua